Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC004223 | Panoply™ Human DEPDC1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC004223 | Panoply™ Human DEPDC1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04786Z | Human DEPDC1 adenoviral particles | Inquiry |
| LV10604L | human DEPDC1 (NM_017779) lentivirus particles | Inquiry |
| LV10605L | human DEPDC1 (NM_001114120) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH001559 | shRNA set against Human DEPDC1(NM_017779.4) | Inquiry |
| SHH277138 | shRNA set against Mouse DEPDC1 (NM_178683.4) | Inquiry |
| SHW001083 | shRNA set against Chicken DEPDC1 (NM_001012928) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCS407663 | Human DEPDC1 ORF Clone (BC065304) | Inquiry |
| CDFH004988 | Human DEPDC1 cDNA Clone(NM_001114120.1) | Inquiry |
| MiUTR1H-02777 | DEPDC1 miRNA 3'UTR clone | Inquiry |
| CDCB162558 | Chicken DEPDC1 ORF Clone (NM_001012928) | Inquiry |
| CDCB186663 | Rabbit DEPDC1 ORF clone (XM_008265076.1) | Inquiry |
| CDCR054974 | Human DEPDC1 ORF clone (NM_001114120.1) | Inquiry |
The DEP structural domain is a globular domain consisting of approximately 90 amino acids that was first identified in three proteins: D. melanogaster Dishevelled, C. elegans EGL-10, and mammalian Pleckstrin, which are involved in Wnt signaling, G protein-coupled receptor signaling, and platelet and neutrophil signaling, respectively. These proteins are involved in Wnt signaling, G protein-coupled receptor signaling and platelet and neutrophil signaling, respectively.
Role of DEPDC1 in Tumor Development and Progression
DEPDC1 (DEP domain containing 1), Several studies have shown that DEPDC1 is aberrantly overexpressed in a wide range of human cancers and acts as an oncogene during tumorigenesis and progression. In a former study, the essential requirement of DEPDC1 to accelerate cell cycle progression and movement through the NF-κB signaling pathway in nasopharyngeal carcinoma has been reported. In other study, researchers found that DEPDC1 plays an oncogenic role in prostate cancer through activation of E2F signaling, which has a broad impact on the progression of HCC.
DEP domain containing 1 (DEPDC1) is a highly conserved protein that has been reported to act as a transcriptional repressor in bladder cancer cells. It represses A20 transcription by forming a complex with ZNF224, which activates the anti-apoptotic pathway through NF-κB via activation of NF-κB. A recent report showed that DEPDC1 promotes JNK-dependent degradation of MCL1 (an anti-apoptotic cell) in HeLa and MCF-7 cells, thereby inhibiting apoptosis. Thus, apoptosis was inhibited. Several reports in bladder, breast and lung cancers suggest that upregulation of DEPDC1 may play an important role in tumor-igenesis.
Molecular Targeted Therapy Strategies against DEPDC1
Given the critical role of DEPDC1 in tumor development and progression, molecular targeted therapy strategies against this gene have gained significant attention. Strategies include gene amplification, gene transfer, and small molecule inhibitors. Preclinical studies have shown that restoring DEPDC1 expression in tumor cells can inhibit tumor growth and metastasis. Moreover, targeting DEPDC1 has the potential to enhance the efficacy of existing cancer therapies and reduce drug resistance.
References: